PIGNATA, SALVATORE ANTONIO
 Distribuzione geografica
Continente #
EU - Europa 1.010
NA - Nord America 946
AS - Asia 198
Continente sconosciuto - Info sul continente non disponibili 5
OC - Oceania 2
SA - Sud America 1
Totale 2.162
Nazione #
US - Stati Uniti d'America 944
IE - Irlanda 316
IT - Italia 273
SE - Svezia 250
CN - Cina 133
PL - Polonia 46
DE - Germania 38
FR - Francia 38
IN - India 32
SG - Singapore 22
FI - Finlandia 12
GB - Regno Unito 10
BE - Belgio 9
VN - Vietnam 8
AT - Austria 5
NL - Olanda 4
A1 - Anonimo 3
AU - Australia 2
CA - Canada 2
IR - Iran 2
RO - Romania 2
A2 - ???statistics.table.value.countryCode.A2??? 1
CH - Svizzera 1
CL - Cile 1
CZ - Repubblica Ceca 1
ES - Italia 1
EU - Europa 1
HK - Hong Kong 1
MK - Macedonia 1
NO - Norvegia 1
RU - Federazione Russa 1
UA - Ucraina 1
Totale 2.162
Città #
Dublin 314
Chandler 300
Nyköping 181
Ashburn 68
Princeton 54
Messina 49
Warsaw 46
Beijing 44
Medford 42
Dearborn 35
Bremen 34
Des Moines 34
Jacksonville 29
Ann Arbor 27
Hyderabad 22
Boardman 12
Cambridge 12
Rome 12
New York 11
Singapore 11
Jinan 10
Brussels 9
Dong Ket 8
Falls Church 8
Shenyang 8
Milan 7
Nanjing 7
Pune 7
Wilmington 7
Hebei 6
Nanchang 6
Redwood City 6
Vittoria 6
Fuzhou 5
Santa Domenica 5
Seattle 5
Taizhou 5
Tianjin 5
Tremestieri Etneo 5
Turin 5
Vienna 5
Changsha 4
Hangzhou 4
Leeds 4
Ningbo 4
Palermo 4
San Mateo 4
Waverly Hall 4
Zhengzhou 4
Bologna 3
Clifton 3
Haikou 3
Helsinki 3
Lanzhou 3
Los Angeles 3
Strasbourg 3
Torino 3
Ancona 2
Bari 2
Brescia 2
Brindisi 2
Catania 2
Clearwater 2
Guangzhou 2
Hefei 2
Iasi 2
Leawood 2
Norwalk 2
Nürnberg 2
Osimo 2
Pescara 2
Pleasant Hill 2
Ravenna 2
Santa Teresa Di Riva 2
Vicenza 2
Agliana 1
Angri 1
Ardabil 1
Augusta 1
Bengaluru 1
Bergamo 1
Berlin 1
Birmingham 1
Boulder 1
Brno 1
Castelfranco Di Sopra 1
Castelnuovo Rangone 1
Chaoyang 1
Chengdu 1
Dallas 1
Decimomannu 1
Duncan 1
Edinburgh 1
Fairfield 1
Florence 1
Floridia 1
Follonica 1
Gardone Val Trompia 1
Geelong 1
Giarre 1
Totale 1.589
Nome #
EMIAGENESIA TIROIDEA, MORBO DI BASEDOW-GRAVES E CARCINOMA DIFFERENZIATO DELLA TIROIDE: UN’ASSOCIAZIONE MOLTO RARA. 176
99mTc-Methoxy-Isobutyl-Isonitrile Scintigraphy Is a Useful Tool for Assessing the Risk of Malignancy in Thyroid Nodules with Indeterminate Fine-Needle Cytology 99
Abnormal 99mTc-MIBI Uptakein left lung mimicking a neoplastic lesion in a young woman with nodular goiter. A rare pitfall of 99mTc-MIBI 77
Prognostic Validity of Dual Tracer PET/CT in the PRRT Enrollment of GEP-NET Patients 77
Association of parathyroid carcinoma and thyroid disorders: A clinical review 73
Peptide Receptor Radionuclide Therapy and Somatostatin 'cold' Analogues Therapy in the Treatment of GEP-NET Patients: Our Center’ Experience 70
Thyroid remnant ablation in differentiated thyroid cancer: searching for the most effective radioiodine activity and stimulation strategy ina real life scenario 68
Braf V600E and 99m-TC MIBI scintigraphy are usefull diagnostic tools in identifying metastatic differentiated thyroid cancer patients refractory to radioiodine therapy. 66
99mTc-methoxy-isobutyl-isonitrile (MIBI) scintigraphy is an useful and cost-effective tool for assessing the risk of malignancy in thyroid nodules with indeterminate fine needle cytology (FNAC) 65
Usefulness of PET-CT scan in recurrent thyroid cancer 64
Complete Response in a Pancreatic Nen with Liver Metastasis after PRRT in association with Lanreotide Autogel/depot: Design of the Prelude Study 63
Differentiating malignant from benign thyroid nodules with indeterminate cytology by 99mTc-MIBI scan: A new quantitative method for improving diagnostic accuracy 62
Renal Function Evaluation in PRRT Retreatments 58
A Single Centre Experience with 223-Radium-Dichloride ((RaCl2)-Ra-223) Therapy 57
223RA-dichloride use in patients affected by bone metastases from castration-resistant prostate cancer: single centre experience 54
Thyroid remnant ablation in differentiated thyroid cancer: searching for the most effective radioiodine activity and stimulation strategy in a real-life scenario 53
un caso di carcinoma delle paratiroidi associato ad adenoma autonomo omolaterale della tiroide 53
Complete response in a pancreatic NEN with liver metastasis after PRRT in association with lanreotide autogel/depot 53
Combined BRAFV600Eanalysis and99mTc-MIBI scintigraphy can be a useful diagnostic tool in differentiated thyroid cancer patients with incomplete bio-chemical response to first radioiodine therapy (RAIT): a pilot investigation 52
Axitinib after Sunitinib in metastatic renal cancer: Preliminary results from Italian "Real-World" SAX Study 52
99mTc-Methoxy-Isobutil-Isonitrile (MIBI) scintigraphy is an useful and cost-effective tool for assessing the risk of malignancy in thyroid nodules with indeterminate fine needle cytology (FNAC) 51
Comparing radioiodine abdominal absorbed dose in differentiated thyroid cancer patients undergone thyroid remnant ablation in either levo-thyroxine withdrawal or after rhtsh stimulation 50
BRAFV600E and 99mTc-MIBI scintigraphy are usefull diagnostic tools in identifying metastatic differentiated thyroid cancer patients refractory to radioiodine therapy 49
Theranosticsin nuclear medicine and oncology 49
Prognostic Validity of Dual Tracer PET/CT In The PRRT Enrollment of GEP-NET Patients 45
Can peptide receptor radionuclide therapy (PRRT) be useful in radioiodine-refractory differentiated thyroid cancer? 44
Is dual tracer PET/CT a prognostic biomarker in the PRRT enrollment of GEP-NET patients? 43
The sensitivity and positive predictive value (PPV) of I-131-post-therapy whole body scan is higher than serum Tg values in detecting metastases in early stage of differentiated thyroid cancer patients 42
PRRT retreatments: renal function evaluation 42
Sequencing radium 223 and other life-prolonging agents in castration-resistant prostate cancer patients 42
From clinical trials to the front line: Vinflunine for treatment of urothelial cell carcinoma at the National Cancer Institute of Naples 41
Post-operative radioiodine therapy (RaIT) as adjuvant therapy in low–intermediate risk differentiated thyroid cancer 38
Very early PSA response to abiraterone in mCRPC patients: A novel prognostic factor predicting overall survival 34
Predictive Comprehensive Geriatric Assessment in elderly prostate cancer patients: The prospective observational scoop trial results 33
Fracture risk and survival outcomes in metastatic castration-resistant prostate cancer patients sequentially treated with abiraterone acetate and RADIUM-223 33
The additional value of 18F-FDG PET and MRI in patients with glioma: A review of the literature from 2015 to 2020 32
Corrigendum: Pazopanib in metastatic renal cancer: A "real-world" experience at national cancer institute "Fondazione G. Pascale" [Front. Pharmacol., 7, 287, (2016)] doi: 10.3389/fphar.2016.00287 31
Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors 28
Pazopanib in metastatic renal cancer: A "real-world" experience at National Cancer Institute "Fondazione G. Pascale" 25
null 24
null 23
Undetectable or low (< 1 ng/ml) postsurgical thyroglobulin values do not rule out metastases in early stage differentiated thyroid cancer patients 22
null 16
Sequencing Life-Prolonging Agents in Castration-Resistant Prostate Cancer Patients: Comparison of Sequences With and Without 223Ra 14
Recombinant human thyrotropin (rhTSH) versus Levo-thyroxine withdrawal in radioiodine therapy of differentiated thyroid cancer patients: differences in abdominal absorbed dose 12
Sequencing radium 223 (RA223) for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) in the daily practice: Preliminary results from a retrospective study in Italian centers 11
Peptide receptor radionuclide therapy plus somatostatin analogues for a neuroendocrine tumour combined and maintenance treatment 11
Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors 8
Totale 2.285
Categoria #
all - tutte 10.331
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.331


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020196 8 2 2 7 1 32 13 33 10 37 19 32
2020/2021281 19 10 77 10 41 6 10 33 32 12 19 12
2021/2022359 6 35 6 7 21 10 8 28 5 39 49 145
2022/20231.015 88 131 49 85 72 92 17 59 376 10 22 14
2023/2024254 21 26 13 37 25 42 16 12 0 27 5 30
2024/202514 14 0 0 0 0 0 0 0 0 0 0 0
Totale 2.285